Get the latest news, insights, and market updates on KYTX (Kyverna Therapeutics, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis
EMERYVILLE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced it will host a conference call on Wednesday, October 29, 2025 at 8:00 AM ET to discuss the interim data from the KYSA-6 Phase 2 clinical trial evaluating KYV-101 in generalized myasthenia gravis (gMG). This data will be shared at the American Association of Neuromuscu Oct 22, 2025 - $KYTX
Wells Fargo Raises Kyverna Therapeutics (KYTX) PT to $27 on Confidence in KYV-101 Stiff Person Syndrome Trial Readout
Kyverna Therapeutics Inc. (NASDAQ:KYTX) is one of the best young stocks with huge upside potential. On October 8, Wells Fargo analyst Derek Archila raised the firm’s price target on Kyverna Therapeutics to $27 from $24, while maintaining an Overweight rating on the shares. Wells Fargo likes the risk/reward on KYV-101’s pivotal stiff person syndrome trial […] Oct 17, 2025 - $KYTX
Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS
KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved expanded disability status scale scores (EDSS) KYV-101 continues to demonstrate a tolerable safety profile, consistent with observations from the first 100 patients treated with KYV-1011 Encouraging early data of KYV-101 in multiple sclerosis highlights broader potential within neuroimmunology autoimmune diseases EMERYVILLE, Calif., Sept. 24, 2025 (GLOBE Sep 24, 2025 - $KYTX
Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025
Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow up Enrollment for registrational Phase 3 portion of KYSA-6 trial in MG on track to initiate by year-end 2025 EMERYVILLE, Calif., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that interim data from the Phase 2 portion of the Sep 15, 2025 - $KYTX
3 Promising Penny Stocks With Market Caps Under $2B
As the United States stock market reaches record highs, investors are keenly watching for opportunities that align with the current economic landscape. Amid expectations of potential interest rate cuts, some investors are turning their attention to penny stocks—an investment area that, despite its outdated moniker, remains relevant today. These smaller or newer companies can offer unique value propositions and growth potential when backed by strong financials. In this article, we will explore... Sep 10, 2025 - $KYTX
Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event
KYV-101 has the potential to deliver durable, drug-free, disease-free remission in myasthenia gravis and set a new treatment standard for stiff person syndrome Innovative FDA-aligned KYSA-6 Phase 3 trial design for myasthenia gravis supports clear and rapid path to BLA Webcast today August 28th, at 11 am ET EMERYVILLE, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients w Aug 28, 2025 - $KYTX
Kyverna Therapeutics to Present at Upcoming Investor Conferences in September
EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the following upcoming conferences: 2025 Wells Fargo Healthcare ConferenceFormat: Fireside ChatDate: Wednesday, September 3rd, 2025Time: 11:00 a.m. ET Morgan Stanley 23rd Annual Global Healthcare Aug 25, 2025 - $KYTX
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) andBLA submission anticipated in 1H 2026 Registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) to include ~60 patients with enrollment to initiate by year-end 2025; interim Phase 2 data expected in Q4 2025 Strong cash position to support upcoming milestones EMERYVILLE, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focus Aug 12, 2025 - $KYTX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple